QuidelOrtho (QDEL) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business Overview and Market Positioning

• Operates in labs, transfusion medicine, point of care, and molecular diagnostics, serving a $50B total addressable market.

• Global reach spans 130+ countries, with 6,600 employees and 3,000 sales/service professionals.

• Over 330 products and more than 1 million patients served daily, with a strong installed base and high customer retention.

• North America generates 58–59% of revenue; China/JPAC 11–21%; EMEA/Latin America 20%.

• 2024 preliminary revenue reported at $2.78B, with Q4 revenue between $702M and $707M.

Leadership, Organizational Changes, and Talent

• Leadership team strengthened with new hires in R&D, HR, legal, and integration initiatives.

• Organization restructured for efficiency, with a flatter model and focus on customer segments.

• New CTO brings deep molecular diagnostics expertise to drive innovation.

• Positive internal and external feedback on new structure and talent.

Segment Performance and Growth Drivers

• Labs business generated $1.1B YTD Q3'24 revenue with stable, mid-single-digit growth and ~15,000 placements.

• Transfusion Medicine achieved $386M YTD Q3'24 revenue and ~7,400 placements; U.S. donor screening winding down.

• Point of Care segment reported $509M YTD Q3'24 revenue, with mid-single-digit growth and ~97,000 Sofia and ~17,000 Triage placements.

• Molecular Diagnostics contributed $17M YTD Q3'24 revenue, seen as the largest near-term growth opportunity, with Savanna platform ramping up.

• Product portfolio covers all care settings, from labs and hospitals to retail and home testing.